
Our publications
Building the foundation for tomorrow’s medicines
In 2006, BioNTech’s co-founders, Ugur Sahin and Özlem Türeci, published their first peer-reviewed paper in the journal Blood: “Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells.” This marked a pivotal moment in their systematic efforts to address key scientific challenges such as improving the stability and efficacy of RNA, which began in the late 1990s.
The 2006 publication was just the beginning. Since then, BioNTech’s co-founders, along with their teams, have published numerous scientific papers spanning various therapeutic modalities. These publications reflect their unwavering vision to translate science into survival by developing innovative therapies and vaccines aimed at improving the health of people worldwide. From foundational discoveries to cutting-edge advancements, BioNTech’s research continues to push the boundaries of medical science, driving progress toward improving or establishing new standards of care.
mRNA based immunotherapies
Sethna Z et al.
RNA neoantigen vaccines prime long-lived CD8(+) T cells in pancreatic cancer
Nature (2025)
Lopez J et al.
Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial
Nature Medicine (2025)
Borgers JSW et al.
Personalized, autologous neoantigen-specific T cell therapy in metastatic melanoma: a phase 1 trial
Nature Medicine (2025)
Forchhammer S et al.
Expression of the tumor antigens NY-ESO-1, tyrosinase, MAGE-A3, and TPTE in pediatric and adult melanoma: a retrospective case control study
Virchows Archive (2024)
Peters D et al.
RNA-encoded Interleukin 2 with Extended Bioavailability Amplifies RNA Vaccine-Induced Antitumor T-cell Immunity
Cancer Immunology Research (2024)
Stadler CR et al.
Preclinical efficacy and pharmacokinetics of an RNA-encoded T cell-engaging bispecific antibody targeting human claudin 6
Science Translational Medicine (2024)
Beck JD et al.
Long-lasting mRNA-encoded interleukin-2 restores CD8(+) T cell neoantigen immunity in MHC class I-deficient cancers
Cancer Cell (2024)
Lang F et al.
Multiple instance learning to predict immune checkpoint blockade efficacy using neoantigen candidates
iScience (2023)
Wang Z et al.
Reducing cell intrinsic immunity to mRNA vaccine alters adaptive immune responses in mice
Molecular Therapy: Nucleic Acids (2023)
Mackensen A et al.
CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial
Nature Medicine (2023)
Wilhelmy C et al.
Polysarcosine-Functionalized mRNA Lipid Nanoparticles Tailored for Immunotherapy
Pharmaceutics (2023)
Rojas LA et al.
Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer
Nature (2023)
Schrörs B et al.
MC38 colorectal tumor cell lines from two different sources display substantial differences in transcriptome, mutanome and neoantigen expression
Frontiers in Immunology (2023)
Vyasamneni R et al.
A universal MHCII technology platform to characterize antigen-specific CD4(+) T cells
Cell Reports Methods (2023)
Noordam L et al.
Systemic T-cell and humoral responses against cancer testis antigens in hepatocellular carcinoma patients
Oncoimmunology (2022)
Lang F et al.
Identification of neoantigens for individualized therapeutic cancer vaccines
Science Translational Medicine (2021)
Salomon N et al.
Local radiotherapy and E7 RNA-LPX vaccination show enhanced therapeutic efficacy in preclinical models of HPV16(+) cancer
Oncoimmunology (2022)
Hotz C et al.
Local delivery of mRNA-encoded cytokines promotes antitumor immunity and tumor eradication across multiple preclinical tumor models
Science Translational Medicine (2021)
Beck JD et al.
mRNA therapeutics in cancer immunotherapy
Molecular Cancer (2021)
Salomon N et al.
A liposomal RNA vaccine inducing neoantigen-specific CD4(+) T cells augments the antitumor activity of local radiotherapy in mice
Oncoimmunology (2020)
Sahin U et al.
An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma
Nature (2020)
Reinhard K et al.
An RNA vaccine drives expansion and efficacy of claudin-CAR-T cells against solid tumors
Science (2020)
Vormehr M et al.
Personalized Neo-Epitope Vaccines for Cancer Treatment
Current Immunotherapeutic Strategies in Cancer (2019)
Grunwitz C et al.
HPV16 RNA-LPX vaccine mediates complete regression of aggressively growing HPV-positive mouse tumors and establishes protective T cell memory
Nature Medicine (2017)
Orlandini von Niessen AG et al.
Improving mRNA-Based Therapeutic Gene Delivery by Expression-Augmenting 3' UTRs Identified by Cellular Library Screening
Molecular Therapy (2019)
Pastor F et al.
An RNA toolbox for cancer immunotherapy
Nature Reviews Drug Discovery (2018)
Shraibman B, Barnea E et al.
Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma
Molecular and Cellular Proteomics (2018)
Rosigkeit S et al.
Monitoring Translation Activity of mRNA-Loaded Nanoparticles in Mice
Molecular Pharmaceutics (2018)
Sahin U, Türeci Ö.
Personalized vaccines for cancer immunotherapy
Science (2018)
Sahin U et al.
Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
Nature (2017)
Stadler CR et al.
Elimination of large tumors in mice by mRNA-encoded bispecific antibodies
Nature Medicine (2017)
Strenkowska M et al.
Cap analogs modified with 1,2-dithiodiphosphate moiety protect mRNA from decapping and enhance its translational potential
Nature Medicine (2017)
Kranz LM et al.
Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy
Nature (2016)
Türeci Ö et al.
Targeting the Heterogeneity of Cancer with Individualized Neoepitope Vaccines
Clinical Cancer Research (2016)
Vormehr M et al.
Mutanome directed cancer immunotherapy
Current Opinion in Immunology (2016)
Vormehr M et al.
Mutanome Engineered RNA Immunotherapy: Towards Patient-Centered Tumor Vaccination
Journal of Immunology Research (2015)
Kreiter S et al.
Mutant MHC class II epitopes drive therapeutic immune responses to cancer
Nature (2015)
Boisguérin V et al.
Translation of genomics-guided RNA-based personalised cancer vaccines: towards the bedside
British Journal of Cancer (2014)
Sahin U, Karikó K, Türeci Ö.
mRNA-based therapeutics--developing a new class of drugs
Nature Reviews Drug Discovery (2014)
Kowalska J et al.
Synthesis, properties, and biological activity of boranophosphate analogs of the mRNA cap: versatile tools for manipulation of therapeutically relevant cap-dependent processes
Nucleic Acids Research (2014)
Kreiter S et al.
Increased Antigen Presentation Efficiency by Coupling Antigens to MHC Class I Trafficking Signals
Journal of Immunology (2008)
Next-generation immunomodulators
Stadler CR et al.
Preclinical efficacy and pharmacokinetics of an RNA-encoded T cell-engaging bispecific antibody targeting human claudin 6
Science Translational Medicine (2024)
Muik A et al.
DuoBody-CD40x4-1BB induces dendritic-cell maturation and enhances T-cell activation through conditional CD40 and 4-1BB agonist activity
Journal for Immunotherapy of Cancer (2022)
Stadler CR et al.
Elimination of large tumors in mice by mRNA-encoded bispecific antibodies
Nature Medicine (2017)
Targeted therapies
Mackensen A et al.
CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial
Nature Medicine (2023)
Explore more

Pipeline

Therapeutic areas
